XRTX

XORTX Therapeutics Inc. NASDAQ Listed Sep 23, 2021

Healthcare ·Biotechnology ·CA · xortx.com

$2.06

-4.19% vs $2.15

Mkt Cap $390.1K

52w Low $1.73 8.8% of range 52w High $5.50

50d MA $2.11 200d MA $2.45

P/E (TTM) -0.0x

EV/EBITDA —

P/B 0.1x

Debt/Equity 0.0x

ROE —

P/FCF -0.1x

RSI (14) 50.70

ATR (14) $0.13

Beta 0.09

50d MA $2.11

200d MA $2.45

Avg Volume 13.1K

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

SIC Code

2834

CIK (SEC)

1729214

Phone

+1 403 455 7727

421 – 7th Avenue SW · Vancouver, BC T2P 4K9 · CA

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 19, 2026	AMC	—	-0.58	—	2.32	+1.7%	+4.7%	-4.9%	-5.6%	+8.7%	+1.3%	—
May 15, 2026	AMC	—	-0.58	—	2.59	-1.9%	+0.4%	-10.8%	+4.7%	-4.9%	-5.6%	—
Feb 26, 2026	AMC	-0.84	-0.45	+46.1%	2.02	-5.9%	+1.5%	+2.4%	-5.2%	+1.5%	+7.4%	—
Nov 14, 2025	AMC	-0.17	-0.13	+22.2%	2.78	+0.7%	-3.6%	+3.0%	-1.1%	-3.3%	+4.9%	—
Aug 14, 2025	AMC	-0.25	-0.19	+24.0%	4.45	+0.0%	-7.6%	-2.7%	-2.5%	-7.7%	+11.1%	—
May 19, 2025	AMC	-0.27	-0.19	+29.6%	4.60	+13.0%	+9.8%	-3.4%	+2.5%	-4.8%	-3.2%	—
May 15, 2025	AMC	-0.29	-0.19	+34.5%	4.70	+5.1%	+13.8%	-14.0%	+9.8%	-3.4%	+2.5%	—
Nov 14, 2024	AMC	-0.38	-0.20	+47.8%	7.00	-6.0%	-8.0%	-4.2%	+5.5%	-3.2%	+0.3%	—
Aug 14, 2024	AMC	-0.50	0.06	+112.0%	7.32	+0.8%	+1.8%	-1.3%	-2.7%	-3.5%	+1.0%	—
May 15, 2024	AMC	-0.45	-1.24	-176.5%	12.45	-2.4%	-5.6%	+6.4%	-1.4%	+6.2%	-0.4%	—
Apr 2, 2024	AMC	-0.68	-0.48	+29.0%	16.88	+2.5%	-3.7%	+8.6%	+4.8%	+5.5%	-2.4%	—
Nov 14, 2023	AMC	-2.04	-6.03	-195.5%	12.80	+1.6%	-5.9%	-4.6%	+30.4%	-15.3%	+0.8%	—
Aug 14, 2023	AMC	-1.56	-0.81	+48.0%	27.47	-1.7%	-0.1%	-0.0%	-3.6%	+0.1%	+15.1%	—
May 15, 2023	AMC	-1.31	-0.99	+24.4%	30.89	+2.0%	-2.2%	+4.2%	+4.6%	+9.4%	+1.1%	—

Institutional (13F) — Top 4 All ↗

#	Manager	Shares	Value	Chg	Period
1	Citadel Advisors Llc	23,116	$52K	New	Jun 2026
2	Kingsview Wealth Management, Llc	15,000	$6K	New	Mar 2026
3	Clearstead Advisors, Llc	277	$92	New	Mar 2026
4	Td Waterhouse Canada Inc.	9	$19	New	Jun 2026

Mutual Funds / ETFs (N-PORT) — Top 0 All ↗

No N-PORT holders found.

Data updated apr 27, 2026 10:54am · Source: financialmodelingprep.com